Predict your next investment

Venture Capital
bjdeliancap.com

See what CB Insights has to offer

Investments

60

Portfolio Exits

3

About Delian Capital

Delian Capital is an investment management agency focused on the transformation and upgrading of China's traditional industries, in a mature or high-growth stage of investment opportunities for small and medium private enterprises. The firm is mainly concerned on areas including new materials, new energy, resource comprehensive utilization based environmental protection, high-end manufacturing, medical health, TMT, and other fields.

Delian Capital Headquarters Location

Suite 1907, Office Tower E1 Oriental Plaza, No.1East

Beijing, Beijing,

China

+86 10 8518 8998 825

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Delian Capital News

Hangzhou Chance Pharmaceuticals Appoints Guobao Zhao as Senior Vice President

Sep 30, 2021

Hangzhou, CHINA HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing transformative inhalation therapies for the world’s most debilitating diseases, today announced that it has appointed Guobao Zhao as Senior Vice President responsible for business development and corporate strategy. Mr. Zhao has extensive experience working in senior management roles. Before joining the Company, Mr. Zhao was Senior Vice President at Delian Capital where he has led Delian’s investments in Amunix, Apexigen, and MicuRx. In addition, Mr.Zhao also represents Delian as a Board member or observer on OnKure, Hummingbird Bioscience, and Chance Pharmaceuticals. Prior to joining Delian Capital, Mr. Zhao served as an R&D Manager at CASI Pharmaceuticals, a publicly traded company listed on Nasdaq. “Guobao is a seasoned leader with significant experience in corporate strategy and business development, which is highly valuable to us as we implement our long-term corporate strategy,” said Dr. Donghao Chen, founder and CEO of Chance Pharmaceuticals. “We believe Guobao’s extensive experience in investing in life science companies and business development skills should help Chance strengthen channel partnerships, develop strategic alliances, and expand our international sales presence.” Mr. Zhao commented, "It has been a tremendous honor to join Chance and serve as Senior Vice President. I very much look forward to working with Chance's management team to solidify its leadership position in the inhalation therapy area. I am confident that Chance is well positioned to capture the market opportunities and achieve rapid further growth." About Hangzhou Chance Pharmaceuticals Co. Ltd. Chance Pharmaceuticals is a clinical-stage biotechnology company focusing on discovering, developing and commercializing transformative inhalation therapies for the world’s most debilitating diseases. For more information, please visit http://www.chancepharmaceuticals.com . Contact Information:

Delian Capital Investments

60 Investments

Delian Capital has made 60 investments. Their latest investment was in Trinova as part of their Series B - II on August 8, 2022.

CBI Logo

Delian Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/2/2022

Series B - II

Trinova

No

3

6/10/2022

Series A

DOiTECH

Yes

1

2/8/2022

Series A - II

AIForceTech

No

5

1/7/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/27/2021

Series A

Subscribe to see more

Subscribe to see more

10

Date

8/2/2022

6/10/2022

2/8/2022

1/7/2022

12/27/2021

Round

Series B - II

Series A

Series A - II

Series A

Series A

Company

Trinova

DOiTECH

AIForceTech

Subscribe to see more

Subscribe to see more

Amount

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

5

10

10

Delian Capital Portfolio Exits

3 Portfolio Exits

Delian Capital has 3 portfolio exits. Their latest portfolio exit was MicuRx Pharmaceuticals on August 05, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/5/2022

IPO

$99M

Public

1

12/21/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/10/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/5/2022

12/21/2021

12/10/2019

Exit

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Delian Capital Team

1 Team Member

Delian Capital has 1 team member, including former Senior Vice President, Guobao Zhao.

Name

Work History

Title

Status

Guobao Zhao

JD Capital Management, CASI Pharmaceuticals, and BioDuro

Senior Vice President

Former

Name

Guobao Zhao

Work History

JD Capital Management, CASI Pharmaceuticals, and BioDuro

Title

Senior Vice President

Status

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.